Search Results for "ADHD"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for ADHD. Results 31 to 40 of 53 total matches.

Addendum: Bupropion Safety in Pregnancy

   
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024  (Issue 1699)
be excluded. In addition, an association between bupropion and attention deficit/hyperactivity disorder (ADHD ...
Our December 11, 2023 article on Drugs for Depression included a single sentence on the safety of bupropion use during pregnancy: "The safety of bupropion during pregnancy has not been established; data from a bupropion pregnancy registry suggested a possible increase in cardiac malformations." A reader asked us to provide more information.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):56   doi:10.58347/tml.2024.1699c |  Show IntroductionHide Introduction

In Brief: Lisdexamfetamine (Vyvanse) for Binge Eating Disorder

   
The Medical Letter on Drugs and Therapeutics • Mar 16, 2015  (Issue 1464)
/drug-pricing-policy. Stimulants ADHD eating disorders lisdexamfetamine vyvanse ...
Lisdexamfetamine dimesylate (Vyvanse), a prodrug of dextroamphetamine previously approved for treatment of attention-deficit/hyperactivity disorder, has now been approved for treatment of moderate-to-severe binge eating disorder (recurrent episodes of compulsive overeating without purging) in adults.FDA approval of lisdexamfetamine for this indication was based on two unpublished, 12-week trials, summarized in the package insert, that randomized patients with moderate-to-severe binge eating disorder to lisdexamfetamine 30 mg/day, which was titrated to 50 mg or, if needed, 70 mg, or to placebo....
Med Lett Drugs Ther. 2015 Mar 16;57(1464):42 |  Show IntroductionHide Introduction

Correction: Panitumumab Dosage

   
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007  (Issue 1262)
in The Medical Letter: Treatment of Lyme Disease Lisdexamfetamine dimesylate (Vyvanse) for ADHD Arformoterol ...
In the CLINICAL STUDIES - Other Cancers paragraph (Med Lett Drugs Ther 2007; 49:35), the dosage in the first line should be 2.5 mg/kg, not 25 mg/kg.
Med Lett Drugs Ther. 2007 Jun 4;49(1262):48 |  Show IntroductionHide Introduction

In Brief: Tegaserod (Zelnorm) Withdrawn

   
The Medical Letter on Drugs and Therapeutics • May 07, 2007  (Issue 1260)
Coming Soon in The Medical Letter: Lisdexamfetamine (Vyvanse) for ADHD Lapatinib (Tykerb) for Breast ...
Tegaserod maleate (Zelnorm – Novartis), a partial serotonin 5-HT4 receptor agonist that increases gastrointestinal motility, was approved by the FDA in 2002 for short-term treatment of constipation-predominant irritable bowel syndrome in women,1 and in 2004 for treatment of chronic constipation in adults ≤65 years old. Its efficacy has not been impressive statistically, but according to Medical Letter consultants some patients with slow-transit constipation have benefited from taking the drug. Diarrhea has been its main adverse effect.2The FDA now has requested that the manufacturer stop...
Med Lett Drugs Ther. 2007 May 7;49(1260):40 |  Show IntroductionHide Introduction

In Brief: Toxicity of Gadolinium-Based Contrast Agents

   
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007  (Issue 1262)
(Vyvanse) for ADHD Arformoterol (Brovana) for COPD Coming Soon in Treatment Guidelines: Drugs ...
Gadolinium-based contrast agents, which are used mainly for magnetic resonance imaging and angiography, were first introduced partly because of the discovery in the 1990’s that iodine-based contrast agents could cause nephrotoxicity and acute renal failure. Some recent reports have suggested, however, that gadolinium-based agents may also be nephrotoxic.1 One patient who developed acute renal failure after use of gadolinium-based contrast had a renal biopsy that showed acute tubular injury.2Moreover, after exposure to gadolinium-based contrast, some patients with severe renal insufficiency,...
Med Lett Drugs Ther. 2007 Jun 4;49(1262):45 |  Show IntroductionHide Introduction

Prilosec, Nexium and Stereoisomers

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 2003  (Issue 1159)
of attention deficit/hyperactivity disorder (ADHD). The d-enantiomer appears to be more active than the l ...
Recently pharmaceutical manufacturers have marketed a stereoisomer of a successful drug nearing patent expiration as a new drug. Examples, such as esomeprazole (Nexium) , levalbuterol (Xopenex), escitalopram (Lexapro) and dexmethylphenidate
Med Lett Drugs Ther. 2003 Jun 23;45(1159):51-2 |  Show IntroductionHide Introduction

Dermal Fillers

   
The Medical Letter on Drugs and Therapeutics • May 07, 2007  (Issue 1260)
and Therapeutics Coming Soon in The Medical Letter: Lisdexamfetamine (Vyvanse) for ADHD Lapatinib (Tykerb ...
Several injectable products are available for soft tissue augmentation of wrinkles and folds. These fillers are often used in conjunction with botulinum toxin type A (Botox) injections.
Med Lett Drugs Ther. 2007 May 7;49(1260):39-40 |  Show IntroductionHide Introduction

A Progestin Implant (Implanon) for Long-Term Contraception

   
The Medical Letter on Drugs and Therapeutics • Oct 09, 2006  (Issue 1245)
in Treatment Guidelines – Drugs for ADHD — November 2006 Surgical Prophylaxis — December 2006 Copyright ...
Implanon (Organon), an implantable contraceptive containing the progestin etonogestrel, has been approved by the FDA. Two other implantable contraceptives, Norplant and Jadelle, which both contain levonorgestrel, are FDA-approved but not marketed in the US.
Med Lett Drugs Ther. 2006 Oct 9;48(1245):83-4 |  Show IntroductionHide Introduction

In Brief: Orlistat OTC for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Jun 18, 2007  (Issue 1263)
and Therapeutics Coming Soon in The Medical Letter: Lisdexamfetamine dimesylate (Vyvanse) for ADHD Arformoterol ...
The FDA has approved over-the-counter (OTC) sale of the weight-loss drug orlistat (Xenical – Roche)1 as alli (GlaxoSmithKline), to be used in combination with a reduced-calorie, low-fat diet. Orlistat binds to gastric and pancreatic lipases, preventing absorption of about 30% of dietary fat with the 120-mg prescription dose, and 25% with the 60-mg OTC dose. A 16-week controlled trial of the OTC dose (60 mg 3 times daily with meals) in overweight, not obese, patients (average BMI 26.8) on a reduced-calorie, low-fat diet found that patients taking the drug lost 1.15 kg more than those taking...
Med Lett Drugs Ther. 2007 Jun 18;49(1263):49 |  Show IntroductionHide Introduction

In Brief: Testing for Ovarian Cancer

   
The Medical Letter on Drugs and Therapeutics • Jul 02, 2007  (Issue 1264)
and Therapeutics Coming Soon in The Medical Letter: Lisdexamfetamine dimesylate (Vyvanse) for ADHD Lybrel ...
Recent publicity about symptoms of ovarian cancer will prompt many questions from patients about testing for the disease. Early-stage epithelial ovarian cancer is potentially curable, with survival rates of 90-95%, but about 75% of women have advanced or metastatic disease at diagnosis. Between physical examination and exploratory surgery, 2 tests are commonly used.1Transvaginal ultrasound (TVUS) images the ovaries better than transabdominal ultrasound. In a study in which 25,327 asymptomatic women were screened with TVUS annually from 1987 to 2005, 364 patients had exploratory surgery, and 44...
Med Lett Drugs Ther. 2007 Jul 2;49(1264):53 |  Show IntroductionHide Introduction